In perhaps the most expected moment in gene patenting matters this year, Myriad Genetics has filed a Notice of Appeal over the court ruling which invalidated its patents over the BRCA1 and BRCA2 genes.
In perhaps the most expected moment in gene patenting matters this year, Myriad Genetics has filed a Notice of Appeal over the court ruling which invalidated its patents over the BRCA1 and BRCA2 genes.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.